Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need. Its approval on June 7, 2021, has been met with an outpouring of opinions from prescribers, insurers, advocacy groups, and hospital systems regarding its risk-benefit profile. Originally approved for all forms of Alzheimer disease (AD), the FDA updated aducanumab's labeling on July 8, 2021, for "treatment in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials." With 6 million people nationally in the United States who suffer from AD and an anticipated one-third of those who may now fulfill the criteria under the revised labeling, the implications of aducanumab's approval continue to generate national interest..
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208401 | PMC |
| http://dx.doi.org/10.1212/CPJ.0000000000001144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generative Artificial Intelligence: Applications in Scientific Writing and Data Analysis in Wound Healing Research.
Adv Skin Wound Care
January 2025
At the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States, Adrian Chen, BS, Aleksandra Qilleri, BS, and Timothy Foster, BS, are Medical Students. Amit S. Rao, MD, is Project Manager, Department of Surgery, Wound Care Division, Northwell Wound Healing Center and Hyperbarics, Northwell Health, Hempstead. Sandeep Gopalakrishnan, PhD, MAPWCA, is Associate Professor and Director, Wound Healing and Tissue Repair Analytics Laboratory, School of Nursing, College of Health Professions, University of Wisconsin-Milwaukee. Jeffrey Niezgoda, MD, MAPWCA, is Founder and President Emeritus, AZH Wound Care and Hyperbaric Oxygen Therapy Center, Milwaukee, and President and Chief Medical Officer, WebCME, Greendale, Wisconsin. Alisha Oropallo, MD, is Professor of Surgery, Donald and Barbara Zucker School of Medicine and The Feinstein Institutes for Medical Research, Manhasset New York; Director, Comprehensive Wound Healing Center, Northwell Health; and Program Director, Wound and Burn Fellowship program, Northwell Health.
Generative artificial intelligence (AI) models are a new technological development with vast research use cases among medical subspecialties. These powerful large language models offer a wide range of possibilities in wound care, from personalized patient support to optimized treatment plans and improved scientific writing. They can also assist in efficiently navigating the literature and selecting and summarizing articles, enabling researchers to focus on impactful studies relevant to wound care management and enhancing response quality through prompt-learning iterations.
View Article and Find Full Text PDFClinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective.
J Cancer Res Ther
December 2024
Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China.
Aim: Toripalimab is the first antitumor programmed cell death protein 1 (PD-1) antibody approved in China. For better patient management, it is important to understand the real-world outcomes of toripalimab in treating patients with lung cancer in the real world outside of clinical trials to improve patient care.
Methods: We retrospectively examined the clinical data of 80 patients with lung cancer who received the PD-1 inhibitor (toripalimab).
Variations and Opportunities in Postnatal Management of Hemolytic Disease of the Fetus and Newborn.
JAMA Netw Open
January 2025
Division of Neonatology, Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Importance: Preventive efforts in pregnancy-related alloimmunization have considerably decreased the prevalence of hemolytic disease of the fetus and newborn (HDFN). International studies are therefore essential to obtain a deeper understanding of the postnatal management and outcomes of HDFN. Taken together with numerous treatment options, large practice variations among centers may exist.
View Article and Find Full Text PDFClubhouse Partnerships with Clinical Services: Current Status and Barriers to Integration.
Community Ment Health J
January 2025
Department of Psychology, Wayne State University, 5057 Woodward Avenue, Detroit, MI, 48202, USA.
The Clubhouse model of psychosocial rehabilitation has supported the recovery of people with serious mental illness for over 75 years, but many of the roughly 350 Clubhouses are not well-integrated into the larger health care system, limiting their reach. This article examines Clubhouses' and psychiatric providers' interactions and experiences to understand the nature of and barriers to partnerships. The directors of Clubhouses affiliated with Clubhouse International were surveyed, examining their attitudes and practices around collaboration with psychiatric providers.
View Article and Find Full Text PDFClinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.
Int J Hematol
January 2025
Associated Department With Mie Graduate School of Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.
This study discusses disseminated intravascular coagulation (DIC) associated with solid cancers and various vascular abnormalities, both of which generally exhibit chronic DIC patterns. Solid cancers are among the most significant underlying diseases that induce DIC. However, the severity, bleeding tendency, and progression of DIC vary considerably depending on the type and stage of the cancer, making generalization difficult.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!